References
- Axon A (2006). Symptoms and diagnosis of gastric cancer at early curable stage. Best Practice & Research Clinical Gastroenterology, 20, 697-708. https://doi.org/10.1016/j.bpg.2006.03.015
- Antonsson B (2001). Bax and other pro-apoptotic Bcl-2 family killer- proteins and their victim, the mitochondrion. Cell Tissue Res, 306, 347-361. https://doi.org/10.1007/s00441-001-0472-0
- Bold RJ, Termuhlen PM< McConkey DJ (1997). Apoptosis, cancer and cancer therapy. Surgical Oncol, 6 ,133-42. https://doi.org/10.1016/S0960-7404(97)00015-7
- Behjati, F, Atri M, Najmabadi H, et al (2005). Prognostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian women. Pathol Oncol Res, 11, 157-63. https://doi.org/10.1007/BF02893392
- Bilim V, Tomita Y, Kawasaki T, et al (1996). Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst, 88 ,686-8.
- Cho YG, Kim CJ, Park CH, et al (2005). Genetic alterations of the KLF6 gene in gastric cancer. Oncogene, 24, 4588-90. https://doi.org/10.1038/sj.onc.1208670
- Cory S, Adams JM (2002). The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer, 2, 647-56. https://doi.org/10.1038/nrc883
- Chipuk JE, Moldoveanu T, Llambi F, et al (2010). The Bcl-2 family reunion. Molecular Cell, 37, 299-310. https://doi.org/10.1016/j.molcel.2010.01.025
- Cleland MM, Norris KL, Karbowski M, et al (2010). Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ, 18, 235-47.
- Callagy GM, Webber MJ, Pharoah PD, et al (2008). Metaanalysis confirms BCL2 is an independent prognostic marker in breast cancer. Bmc Cancer, 8,153. https://doi.org/10.1186/1471-2407-8-153
- Favaloro B, Allocati N, Graziano V, et al (2012). Role of Apoptosis in disease. AGING Journal, 4, 5.
- Faderl S, Keating MJ, Do K.A ,et al (2002). Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia, 16, 1045-52. https://doi.org/10.1038/sj.leu.2402540
- Fontanini G, Vignati S, Bigini D, et al (1995). Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-smallcell lung cancer. Br J Cancer, 71, 1003-7. https://doi.org/10.1038/bjc.1995.193
- Hopkins J, Guilford P, Harraway J, et al (1998). Ecadheringermline mutations in familial gastric cancer. National Institutes of Health, 392, 402-5.
- Hirata H, Hinoda Y, Nakajima K, et al (2009). The BCL2-938CC Genotype Has Poor Prognosis and Lower Survival in Renal Cancer. J Urol, 182, 721-7. https://doi.org/10.1016/j.juro.2009.03.081
- Kim J.P, Lee JH, Kim SJ, et al (2005). Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer, 1, 125-33.
- Kamesaki. H (1998). Mechanisms involved in chemotherapyinduced apoptosis and their implications in cancer chemotherapy. Inter J Hematol, 68, 29-43. https://doi.org/10.1016/S0925-5710(98)00038-3
- Keshgegian AA, Johnston E, Cnaan A (1998). Bcl-2 oncoprotein positivity and high MIB- 1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol, 110, 443-9. https://doi.org/10.1093/ajcp/110.4.443
- Karasek M, et al (2002). Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer. Neuro Endocrinol Lett, 1, 55-60.
- Lehnerdt G.F, Franz P, Bankfalvi A, et al (2009). The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol, 20, 1094-99. https://doi.org/10.1093/annonc/mdn763
- Milne A.N, Carneiro F, Morain C, et al (2009). Nature meets nurture: molecular genetics of gastric cancer. Human Genetics, 126, 615-28. https://doi.org/10.1007/s00439-009-0722-x
- Martinou J.C, Youle RJ (2011). Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Developmental Cell, 21, 92-101. https://doi.org/10.1016/j.devcel.2011.06.017
- Moul JW (2012). Angiogenesis, p53, Bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol, 35, 399-407.
- MowlaS, Emadi Bayegi M, Ziaee SA (2005). Evaluating expression and potential diagnostic and prognostic values of Survivin in bladder tumors a preliminary report. Printed in IRAN, 2, 141-7.
- Mistry,T (2008). Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl 2 expression. BJU international, 1317-22.
- Ofner D, Riehemann K, Maier H, ssssss (1995). Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer, 72, 981-985. https://doi.org/10.1038/bjc.1995.446
- Parkin, D, Bray F, Ferlay J, et al (2002). Global cancer statistics. CA Cancer J, 55, 74-108.
- Parkin DM, Bray FI, Devesa SS, et al (2001). Cancer burden in the year 2000. The global picture. European Journal of Cancer, 37 ,4-66.
- Pinto E, Roviello F, Stefano A.D (1994). Early gastric cancer: report on 142 patients observed over 13 years. Jpn J Clin Oncol, 24, 12-19.
- Rostamizadeh L, Fakhrjou A, Montazeri V, et al (2013). Bcl-2 Gene expression in human breast cancers in Iran. Asian Pac J Cancer Prev, 14, 4209-14. https://doi.org/10.7314/APJCP.2013.14.7.4209
- Sung, N, Choi KS, Park EC, et al. (2007). Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer, 97, 700-4. https://doi.org/10.1038/sj.bjc.6603893
- Seto M, Jaeger U, Hockett RD, et al. (1988). Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J, 7, 123-31.
- Sadjadi A, Nouraie M, Ghorbani A, et al (2009). Epidemiology of breast cancer in the Islamic republic of Iran: first results from a population-based cancer registry. East Mediterr Health J, 15, 1426-31.
- Sulkowska M, Famulski W, Sulkowski S, et al (2003). Correlation between Bcl-2 protein expression and some clinicopathological features of oral squamous cell carcinoma. Pol J Pathol, 54, 49-52.
- Silvestrini R, Benini E, Veneroni S, et al (1996). p53 and Bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol, 14, 1604-10.
- Stackhouse GB, Sesterhenn IA, Bauer JJ, et al (1999). p53 and Bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol, 162, 2040-5. https://doi.org/10.1016/S0022-5347(05)68095-0
- WHO,(2004) Initiative for vaccine research team of the department of immunization, vaccines and biologicals. epidemiology of helicobacter pylori and gastric cancer. in proceedings of the fourth global vaccine research forum.
- Young RL, Korsmeyer SJ (1993). A negative regulatory element in the Bcl-2 5’- untranslated region inhibits expression from an upstream promoter. Mol Cell Biol, 13(6) ,3686-3697. https://doi.org/10.1128/MCB.13.6.3686
- Yan JJ, Chen FF, Tsai YC, et al (2009). Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology, 53, 6-11.
- Zhang GJ, Kimijima I, Tsuchiya A et al (1998). The role of Bcl-2 expression in breast carcinomas [review]. Oncol Rep, 5, 1211-6.
- Zinkel S, Gross A, Yang E (2006). BCL2 family in DNA damage and cell cycle control. Cell Death Differ, 13, 1351-9. https://doi.org/10.1038/sj.cdd.4401987
- Zhang GJ, Kimijima I, Tsuchiya A, et al (1998). The role of Bcl-2 expression in breast carcinomas (Review). Oncol Rep, 5, 1211-16.